ABOUT / 08
About TB-500 MD
Who keeps this notebook, how the evidence is charted, and where the reading stops.
What this site is
TB-500 MD keeps a rounds notebook on the published research covering Thymosin Beta-4 and its Ac-LKKTETQ fragment. It reads each paper the way a journal club works a case — findings summarized, caveats noted, the citation logged in the margin — and it charts the evidence without ever writing an order from it. The 'MD' in the name marks that reading posture toward the literature; it is no clinic and keeps no clinical staff. Nothing is sold, prescribed, dispensed, or dosed here, and no medical instruction is given. What the notebook offers is a cited account of what the studies report.
How we work
The notebook runs on primary sources. A quantitative statement earns a place only when a specific peer-reviewed study, registered trial, or regulatory record backs it, and each entry on /references can be traced to that source. Results that failed to replicate are charted beside those that held, and a single encouraging animal finding is never promoted to a settled human fact. Where marketing blurs the synthetic fragment into full-length Tβ4, the notebook keeps the distinction the structural biology draws. No vendor is linked; outbound pointers go to PubMed, ClinicalTrials.gov, the NIH, and journal pages.
What we do not do
No named physician, advisor, or reviewer signs this notebook; it carries no byline because it reports the record rather than treating from it. It prescribes no dose for human use, offers no treatment plan, and arranges no consultation, referral, or sale. It does not judge whether a given purchase, import, or use is lawful where you are — that is a licensed attorney's question. Regulatory standing changes; each status is dated to its page, and the issuing agency stays the final word.